On August 27, 2020 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, reported that Walter Klemp, Chairman and Chief Executive Officer, will present at the LD Micro 500 Virtual Investor Conference being held virtually on Tuesday, September 1st, at 4:40pm ET (Press release, Moleculin, AUG 27, 2020, View Source [SID1234564091]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)
Details of the presentation are below:
Event:
LD Micro 500 Virtual Investor Conference
Date:
September 1st, 2020
Time:
4:40pm ET
Link:
Additionally, the Company will hold 1-on-1 virtual investor meetings at the conference. Investors attending the conference virtually who are interested in meeting with Company management should contact their LD Micro representatives.